News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

INSYS Therapeutics Announces NDA Acceptance of its Fentanyl SL Spray



5/12/2011 10:34:54 AM

Insys Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL.PK) today announced that the Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Fentanyl SL Spray. The FDA will notify Insys of its PDUFA date in the 74-day letter which is expected in the upcoming weeks.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES